An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04620811 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Gastritis
Eosinophilic Duodenitis

Interventions

DRUG: lirentelimab

Sponsor

Allakos Inc.